Closing the circle on HIV--or not.
Mascolini
M
M
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D016049:Didanosine / Q000008:administration & dosage / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006678:HIV / Q000235:genetics / Q000302:isolation & purification; D015658:HIV Infections / Q000188:drug therapy / Q000503:physiopathology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use; D019888:Nelfinavir; D011379:Prognosis; D012367:RNA, Viral / Q000097:blood; D016047:Zalcitabine / Q000008:administration & dosage / Q000627:therapeutic use; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
D000998:Antiviral Agents; D015415:Biomarkers; D017320:HIV Protease Inhibitors; D007376:Interleukin-2; D012367:RNA, Viral; D015215:Zidovudine; D016047:Zalcitabine; D019888:Nelfinavir; D016049:Didanosine